Literature DB >> 1282009

Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis.

I E Coremans1, E C Hagen, M R Daha, F J van der Woude, E A van der Voort, C Kleijburg-van der Keur, F C Breedveld.   

Abstract

OBJECTIVE: To determine the occurrence of antineutrophil cytoplasmic antibodies (ANCA) and the specificity of these antibodies (Ab) in serum from patients with rheumatoid arthritis (RA) and patients with rheumatoid arthritis complicated by vasculitis (rheumatoid vasculitis [RV]).
METHODS: ANCA was detected with an indirect immunofluorescence test on ethanol-fixed granulocytes. Ab against the cytoplasmic antigens proteinase-3, elastase, lactoferrin (LF), and myeloperoxidase were measured by enzyme-linked immunosorbent assay.
RESULTS: ANCA were found in the serum of 43% of 49 patients with RV and in 36% of 50 patients with RA. Anti-LF Ab occurred more frequently in RV patients (45%) than in RA patients (4%), whereas reactivity against the other cytoplasmic antigens did not differe significantly between these groups.
CONCLUSION: Anti-LF Ab in serum of patients with RA may be useful in the diagnosis of vasculitis in RA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282009     DOI: 10.1002/art.1780351210

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  37 in total

Review 1.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.

Authors:  H Chikazawa; K Nishiya; A Matsumori; K Hashimoto
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

Review 4.  Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace.

Authors:  Shweta Kishore; Lisa Maher; Vikas Majithia
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

5.  N-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid.

Authors:  W A De Backer; B Amsel; P G Jorens; L Bossaert; P S Hiemstra; P van Noort; F J van Overveld
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

6.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

Review 7.  The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens.

Authors:  A Wiik; L Stummann; L Kjeldsen; N Borregaard; S Ullman; S Jacobsen; P Halberg
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

8.  Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity.

Authors:  E Röther; D Metzger; B Lang; I Melchers; H H Peter
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

9.  Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?

Authors:  B E Ballieux; K T Zondervan; P Kievit; E C Hagen; L A van Es; F J van der Woude; M R Daha
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

Authors:  J A Savige; B Paspaliaris; R Silvestrini; D Davies; T Nikoloutsopoulos; A Sturgess; J Neil; W Pollock; K Dunster; M Hendle
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.